10-QPeriod: Q2 FY2005

BIOGEN INC. Quarterly Report for Q2 Ended Jun 30, 2005

Filed July 27, 2005For Securities:BIIB

Summary

Biogen Idec Inc. reported its financial results for the quarter and six months ended June 30, 2005. The company experienced significant revenue growth, primarily driven by its flagship multiple sclerosis (MS) drug, AVONEX. While overall revenue and net income showed positive trends compared to the prior year, investors should pay close attention to the significant increase in operating expenses, particularly in research and development and selling, general, and administrative costs. This increased investment in R&D signals a commitment to future growth and product pipeline development, but it also impacts current profitability. Investors will want to monitor the return on these investments and the continued performance of key products like AVONEX.

Key Highlights

  • 1Revenue for the three months ended June 30, 2005, increased by 25% to $311.0 million compared to $249.5 million in the same period of 2004.
  • 2Net income for the quarter rose to $81.4 million, or $0.24 per diluted share, from $51.8 million, or $0.15 per diluted share, in the prior year's second quarter.
  • 3AVONEX sales grew by 21% to $222.4 million for the second quarter of 2005, underscoring its continued strength as a key revenue driver.
  • 4Total operating expenses increased significantly, with R&D expenses up 30% and SG&A expenses up 27% for the six-month period, reflecting investments in pipeline development and commercialization efforts.
  • 5The company reported a strong balance sheet with total assets of $4,350.4 million as of June 30, 2005, and cash and cash equivalents of $707.1 million.
  • 6Biogen Idec continues to be an accelerated filer, indicating its significant market capitalization and adherence to enhanced SEC reporting requirements.

Frequently Asked Questions

The primary driver of revenue growth was the strong performance of AVONEX, Biogen Idec's key drug for treating multiple sclerosis. AVONEX sales increased by 21% year-over-year, contributing significantly to the overall 25% increase in quarterly revenue.

Operating expenses saw a notable increase. Research and Development (R&D) expenses rose by 30% and Selling, General, and Administrative (SG&A) expenses increased by 27% for the six-month period. This reflects the company's investment in its product pipeline and commercial operations.

Biogen Idec maintained a solid financial position, reporting $707.1 million in cash and cash equivalents as of June 30, 2005. This indicates sufficient liquidity to fund operations and future investments.

Yes, Biogen Idec is identified as an accelerated filer. This designation means the company meets specific size and filing history requirements, subject to enhanced SEC reporting and disclosure obligations.